De-escalating rituximab dose results in stability of clinical, radiological, and serum neurofilament levels in multiple sclerosis.

Background: Phase II and observational studies support the use of rituximab in multiple sclerosis. Standard protocols are lacking, but studies suggest comparable efficacy between low- and high-dose regimens.

Objective: To evaluate effectiveness and safety of de-escalating rituximab dose from 1000 to 500 mg/6 months in multiple sclerosis.

Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis.

Importance: Therapeutic options for patients with secondary progressive multiple sclerosis (SPMS) are limited.

Objective: To analyze disability progression in patients with SPMS treated with rituximab compared with matched control patients never treated with rituximab.

Design, Setting, And Participants: This retrospective cohort study analyzed data obtained from patients with SPMS at 3 multiple sclerosis centers located in Basel and Lugano, Switzerland, and Amsterdam, the Netherlands, from 2004 to 2017.

Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland.

Background: Despite positive results from phase II and observational studies, Rituximab (RTX) is not currently approved for multiple sclerosis (MS) treatment and can only be used off-label.

Objective: To characterize MS patients treated with RTX and investigate its effectiveness and safety in a clinical practice setting.

Methods: Observational analysis of data collected from MS patients at the Neurocenter of Southern Switzerland.